This website contains information about
INBRIJA® (levodopa inhalation powder)
M-INB-UK-0047
Date of preparation: December 2025
This website is intended for healthcare professionals from the United Kingdom only. Adverse event reporting information can be found at the bottom of the page.
Changes in maintenance regimens do
not reliably eliminate symptom return
Meals or gut motility problems interfere
with administration of oral levodopa
Symptoms return unexpectedly
or unpredictably
Onset of action is too slow with oral dose,
contributing to morning OFF episodes,
as effect wears off overnight
OFF episodes may occur even with optimised baseline and adjunctive therapy.2
Adapted from Isaacson SH et al. Clin Park Relat Disord. 2022;7:1001612
M-INB-UK-0047
Date of preparation: December 2025